JPM new target $110, CS $56. Even the most bearish analyst which is Chardan has a target of $29. This really makes no sense. I almost sold yesterday after hours but saw the sell off was on fairly light volume. Unfortunately that was a mistake and I didn't see this coming. I may add to my position tomorrow and average down. Very cheap asset and now a takeover target.
Yeah that will go over well, bmrn blocking Etep - essentially the good folks in bmrn mgmt killing kids to make a profit. Drisa doesn't even work. You will see such an uprising from parents of DMD parents - bmrn will suffer serious backlash if this even happens
People keep blaming AF's article. I really don't thing his article had much of an effect today. If you notice the stock opened up, after the article was released. MANY biotech's were down 4,5,6+% today. SRPT has had a decent run so people took profits - maybe some shorts pilled in. Anyway there is going to be a significant data release before the panel meeting. If the good news continues, we're in the 40's.
It depends on your time horizon & your opinion of management. I personally sold around 17.90-18 after hours yesterday. The part that really bothers me is the company has material information from the FDA regarding Rindo and sat on it until the CC. That it not cool. They have a lot in the pipeline but you might not see anything meaningful until late next year. The is a Rindo readout later this year/early 2016. However, if it's recommended the trial continue, there won't be anymore Rindo data until end of 2016. Therefore you probably see this drift down to the low teens again. There are better plays then CLDX but due your own DD
Baird enthusiastic after speaking with management and is more excited that even for Etep prospects. Sun goes to hold only cause srpt reaches target- says stock might be a little ahead of itself. Personally I think Sun is missing the boat. We're within 4 months of panel meeting which could bring SRPT to 60+ easy. I'll buy more if it pulls back. We're less than 3 weeks away from NDA acceptance. Still about 40% of the float short